Medrano, M.
Contreras, M.
Caballero-Velázquez, T.
Martínez, L.
Bejarano-García, J. A.
Calderón-Ruiz, R.
García-Calderón, C. B.
Rosado, I. V.
Pérez-Simón, J. A. http://orcid.org/0000-0003-3616-6101
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI17/02177, PI20/01792, DTS20/00165, FI16/00412)
Sociedad Española de Hematología y Hemoterapia (FEHH-Janssen 2020, FEHH 2021)
Article History
Received: 4 July 2023
Revised: 1 February 2024
Accepted: 8 February 2024
First Online: 9 March 2024
Competing interests
: There are two patents for this Project: “Use of cannabinoids as ceramide-generating anticancer agents in tumours of the hematopoietic and lymphoid tissues” (EP3226847A2; US2018353461A1; WO2016087649A2; WO2016087649A3) and “Indazole derivatives for cancer treatment” (EP3449922A1; EP3449922A4; ES2644216A1; ES2644216B1; US2020281897A1; WO2017186999A1).
: All research involving human material or animal samples was approved by the Ethical Committee for Clinical Research (CEIC) of the University Hospital Virgen del Rocío and was conducted in accordance with the Declaration of Helsinki.